These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 29107277)

  • 1. Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?
    Damodaran S; Kyriakopoulos CE; Jarrard DF
    Urol Clin North Am; 2017 Nov; 44(4):611-621. PubMed ID: 29107277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.
    Kunath F; Goebell PJ; Wullich B; Sikic D; Kahlmeyer A
    World J Urol; 2020 Mar; 38(3):601-611. PubMed ID: 30830274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
    Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
    Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials.
    van Soest RJ; de Wit R
    BMC Med; 2015 Dec; 13():304. PubMed ID: 26695172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer.
    Parker DC; Cookson MS
    Investig Clin Urol; 2020 Feb; 61(Suppl 1):S3-S7. PubMed ID: 32055749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)].
    Miller K
    Aktuelle Urol; 2019 Dec; 50(6):625-628. PubMed ID: 30919390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
    Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
    Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.
    Marino P; Sfumato P; Joly F; Fizazi K; Oudard S; Culine S; Habibian M; Boher JM; Gravis G
    Eur J Cancer; 2017 Oct; 84():27-33. PubMed ID: 28780479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.
    Stein MN; Hussain M; Stadler WM; Liu G; Tereshchenko IV; Goodin S; Jeyamohan C; Kaufman HL; Mehnert J; DiPaola RS
    Clin Genitourin Cancer; 2016 Feb; 14(1):22-7. PubMed ID: 26476589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
    Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
    BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
    Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
    J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
    Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
    Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemohormonal Therapy for Hormone-Sensitive Prostate Cancer: A Review.
    Kyriakopoulos CE; Liu G
    Cancer J; 2016; 22(5):322-325. PubMed ID: 27749324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
    Wang Y; Dai B; Ye DW
    Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management.
    Gudenkauf LM; Gray S; Gonzalez BD; Sachdeva A; Autio K
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433126. PubMed ID: 38788186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
    Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
    Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.